Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PKM2
REST API REST API
Homo sapiens
PKM2 is differentially expressed in 280 experiments: 105 organism parts: liver, skeletal muscle, ... (103 more);, 184 disease states: normal, breast carcinoma, ... (182 more);, 96 cell types 242 cell lines 31 compound treatments and 73 other conditions.
Synonyms PK3, THBP1, OIP3
Orthologs Pkm2 (Rattus norvegicus)   pkm2b (Danio rerio)   F1P4U1_CHICK (Gallus gallus)   Pkm2 (Mus musculus)   A5D984_BOVIN (Bos taurus)   CDC19 (Saccharomyces cerevisiae)   F6UHT5_CIOIN (Ciona intestinalis)   pkm2a (Danio rerio)   PYK2 (Saccharomyces cerevisiae)   CG7362 (Drosophila melanogaster)   CG7069 (Drosophila melanogaster)   CG2964 (Drosophila melanogaster)   PyK (Drosophila melanogaster)   pkm2 (Xenopus laevis)   O62755_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, glucose metabolic process, protein binding, flagellum, cytoplasm, response to hypoxia, soluble fraction, glycolysis, programmed cell death, response to nutrient, pyruvate kinase activity, ATP binding, magnesium ion binding, potassium ion binding, nucleus, nucleotide binding, carbohydrate metabolic process, ATP biosynthetic process, transferase activity, response to gravity, mitochondrion, pyruvate biosynthetic process, ADP binding, skeletal muscle tissue regeneration, organ regeneration, response to insulin stimulus, liver development, response to organic substance, response to muscle inactivity
InterPro Term Pyr_Knase, Pyrv_Knase_brl, Pyrv_Knase_C
UniProt Accession Q8WUW7, Q9UKK4, P14618, B4DNK4, B4DUU6, E7EUJ4, E7EUQ8, E9PF79
Search EB-eye ENSG00000067225
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (35 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-3202, E-GEOD-6013
MOLT4
2
E-MTAB-62, E-MTAB-37
sk-mel-28
1
E-MTAB-62
snb-19
1
E-MTAB-62
NCI-H226
1
E-MTAB-62
NA19102
1
E-GEOD-19480
236 more value(s).


Cell type

studied in E-MEXP-1242, E-GEOD-22373, E-GEOD-21668, E-MEXP-750, E-GEOD-360, ... (45 experiments)

Factor Value U/D Experiments
macrophage
1
3
E-GEOD-22373, E-GEOD-5099, E-GEOD-360, E-GEOD-3982
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
centroblast
1
E-TABM-702
type I helper T cell
1
E-GEOD-3982
bronchial epithelial cell
1
E-TABM-145
testis - germ cell
1
E-AFMX-5
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-2280, E-GEOD-16363, E-MTAB-62, ... (61 experiments)

Factor Value U/D Experiments
gastric carcinoma
2
E-GEOD-2685, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-GEOD-2514, E-MEXP-231
obesity
2
E-MTAB-62, E-GEOD-2508
prostate carcinoma
2
E-GEOD-96, E-MTAB-62
glioblastoma
1
2
E-GEOD-4290, E-MTAB-62, E-GEOD-4412
178 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-TABM-782, ... (22 experiments)

Factor Value U/D Experiments
CNOT7+CNOT8
1
E-MEXP-2218
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
granulocyte-colony stimulating factor
1
E-GEOD-7400
17beta-estradiol
4
1
E-GEOD-4006
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
25 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1563, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-MEXP-2359, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-TABM-147, E-GEOD-21138, E-GEOD-21887, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-GEOD-2152, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-2724, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-21612, E-MEXP-2657, E-GEOD-20540, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (32 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-21750, E-GEOD-17636, E-GEOD-2487, E-GEOD-4600

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-19330, E-GEOD-18791

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-MEXP-973, E-GEOD-21909, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.418 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM